Craig Lindsley

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming cutting-edge research into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read More

Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming Vanderbilt researchers’ work into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read More

Days’ work to identify highly potent and selective 5-HT2B antagonists was recognized by the Rosalind Franklin Society Read More

The Warren Center for Neuroscience Drug Discovery opened its doors to the Nashville community to share firsthand the pioneering work it is conducting on Alzheimer’s disease, Parkinson’s disease, addiction, and more. Read More

Using computer-aided drug design, the labs of Heidi Hamm, Jens Meiler, and Craig Lindsley generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read More

Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read More

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read More

Research by David Merryman and Craig Lindsley has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. The article, “Development of a Peripherally Restricted… Read More

Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and… Read More